Vilazodone, a Selective Serotonin Reuptake Inhibitor with Diminished Impact on Methylphenidate-Induced Gene Regulation in the Striatum: Role of 5-HT1A Receptor
AbstractSelective serotonin reuptake inhibitors (SSRIs), including fluoxetine, are frequently combined with medical psychostimulants such as methylphenidate (Ritalin), for example, in the treatment of attention-deficit hyperactivity disorder/depression comorbidity. Co-exposure to these medications also occurs with misuse of methylphenidate as a recreational drug by patients on SSRIs. Methylphenidate, a dopamine reuptake blocker, produces moderate addiction-related gene regulation. Findings show that SSRIs such as fluoxetine given in conjunction with methylphenidate potentiate methylphenidate-induced gene regulation in the ...
Source: Molecular Neurobiology - March 27, 2024 Category: Neurology Source Type: research
An LC ‐MS/MS method for the determination of drugs of abuse included THC‐COOH, EtG, and NPS, using a single hair extraction sample
A rapid method was developed involving a single 25 mg hair extraction procedure and fourLC-MS/MS methods using the same chromatographic phases and column, for the identification andquantification of commonly abused drugs and/or their metabolites, including amphetamines, cocaine,opioids, cannabinoids, THC-COOH and EtG, and new psychoactive substances as syntheticcannabinoids, phenethylamines, synthetic opioids, methylphenidate, cathinones, and tryptamines. AbstractHair analysis plays an important role in the determination of drugs of abuse in both forensic and clinical toxicology investigations. The analysis of different su...
Source: Drug Testing and Analysis - March 27, 2024 Category: Drugs & Pharmacology Authors: Valentina Longo,
Giulia Stocchero,
Manuela Lucchiari,
Giovanni Michele Marchio,
Flora Donini,
Francesco Ingenito,
Lucia Bertoldi,
Lucia Pecoraro,
Adriano Anesi,
Donata Favretto Tags: RESEARCH ARTICLE Source Type: research
Medication Treatment for ADHD Linked to Lower Two-Year Risk of Dying
People with attention-deficit/hyperactivity disorder (ADHD) who begin taking medications for the condition within three months of their diagnosis may have a lower risk of dying within two years compared with their peers who do not take ADHD medications, astudy inJAMA has found.Zheng Chang, Ph.D., of the Karolinska Institutet in Stockholm and colleagues examined data from 148,578 Swedish individuals aged 6 to 64 years who had an incident diagnosis of ADHD from 2007 through 2018 and no ADHD medication dispensation for at least 18 months prior to their diagnosis. They followed the patients from ADHD diagnosis for two years or...
Source: Psychiatr News - March 15, 2024 Category: Psychiatry Tags: ADHD attention-deficit/hyperactivity disorder JAMA Karolinska Institutet medication mortality stimulants unnatural deaths Source Type: research
Attention-Deficit Hyperactivity Disorder (ADHD) Medication Use Trajectories Among Women in the Perinatal Period
ConclusionWe found that approximately 60% of women discontinued or interrupted their ADHD medication around pregnancy, and those who continued differed in sociodemographic and clinical factors that may reflect more severe ADHD. (Source: CNS Drugs)
Source: CNS Drugs - March 15, 2024 Category: Neurology Source Type: research
Stimulant prodrugs: A pharmacological and clinical assessment of their role in treating ADHD and binge-eating disorder
Adv Pharmacol. 2024;99:251-286. doi: 10.1016/bs.apha.2023.10.002. Epub 2023 Oct 25.ABSTRACTIn this review, we critically evaluate the contribution of prodrugs to treating two related psychiatric disorders, attention-deficit hyperactivity disorder (ADHD) and binge-eating disorder (BED). ADHD is characterized by inattentiveness, distractibility, impulsiveness, and hyperactivity. BED is also an impulse-control disorder which leads to frequent, compulsive episodes of excessive eating (binges). Lisdexamfetamine (LDX; prodrug of d-amphetamine) is approved to treat both ADHD and BED. Serdexmethylphenidate (SDX; prodrug of d-threo...
Source: Advances in Pharmacology - March 11, 2024 Category: Drugs & Pharmacology Authors: David J Heal Jane Gosden Sharon L Smith Source Type: research
Stimulant prodrugs: A pharmacological and clinical assessment of their role in treating ADHD and binge-eating disorder
Adv Pharmacol. 2024;99:251-286. doi: 10.1016/bs.apha.2023.10.002. Epub 2023 Oct 25.ABSTRACTIn this review, we critically evaluate the contribution of prodrugs to treating two related psychiatric disorders, attention-deficit hyperactivity disorder (ADHD) and binge-eating disorder (BED). ADHD is characterized by inattentiveness, distractibility, impulsiveness, and hyperactivity. BED is also an impulse-control disorder which leads to frequent, compulsive episodes of excessive eating (binges). Lisdexamfetamine (LDX; prodrug of d-amphetamine) is approved to treat both ADHD and BED. Serdexmethylphenidate (SDX; prodrug of d-threo...
Source: Advances in Pharmacology - March 11, 2024 Category: Drugs & Pharmacology Authors: David J Heal Jane Gosden Sharon L Smith Source Type: research
Stimulant prodrugs: A pharmacological and clinical assessment of their role in treating ADHD and binge-eating disorder
Adv Pharmacol. 2024;99:251-286. doi: 10.1016/bs.apha.2023.10.002. Epub 2023 Oct 25.ABSTRACTIn this review, we critically evaluate the contribution of prodrugs to treating two related psychiatric disorders, attention-deficit hyperactivity disorder (ADHD) and binge-eating disorder (BED). ADHD is characterized by inattentiveness, distractibility, impulsiveness, and hyperactivity. BED is also an impulse-control disorder which leads to frequent, compulsive episodes of excessive eating (binges). Lisdexamfetamine (LDX; prodrug of d-amphetamine) is approved to treat both ADHD and BED. Serdexmethylphenidate (SDX; prodrug of d-threo...
Source: Advances in Pharmacology - March 11, 2024 Category: Drugs & Pharmacology Authors: David J Heal Jane Gosden Sharon L Smith Source Type: research
Stimulant prodrugs: A pharmacological and clinical assessment of their role in treating ADHD and binge-eating disorder
Adv Pharmacol. 2024;99:251-286. doi: 10.1016/bs.apha.2023.10.002. Epub 2023 Oct 25.ABSTRACTIn this review, we critically evaluate the contribution of prodrugs to treating two related psychiatric disorders, attention-deficit hyperactivity disorder (ADHD) and binge-eating disorder (BED). ADHD is characterized by inattentiveness, distractibility, impulsiveness, and hyperactivity. BED is also an impulse-control disorder which leads to frequent, compulsive episodes of excessive eating (binges). Lisdexamfetamine (LDX; prodrug of d-amphetamine) is approved to treat both ADHD and BED. Serdexmethylphenidate (SDX; prodrug of d-threo...
Source: Advances in Pharmacology - March 11, 2024 Category: Drugs & Pharmacology Authors: David J Heal Jane Gosden Sharon L Smith Source Type: research
Stimulant prodrugs: A pharmacological and clinical assessment of their role in treating ADHD and binge-eating disorder
Adv Pharmacol. 2024;99:251-286. doi: 10.1016/bs.apha.2023.10.002. Epub 2023 Oct 25.ABSTRACTIn this review, we critically evaluate the contribution of prodrugs to treating two related psychiatric disorders, attention-deficit hyperactivity disorder (ADHD) and binge-eating disorder (BED). ADHD is characterized by inattentiveness, distractibility, impulsiveness, and hyperactivity. BED is also an impulse-control disorder which leads to frequent, compulsive episodes of excessive eating (binges). Lisdexamfetamine (LDX; prodrug of d-amphetamine) is approved to treat both ADHD and BED. Serdexmethylphenidate (SDX; prodrug of d-threo...
Source: Advances in Pharmacology - March 11, 2024 Category: Drugs & Pharmacology Authors: David J Heal Jane Gosden Sharon L Smith Source Type: research
